4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics (Nasdaq: FDMT) announced that on December 9, 2025 its compensation committee granted 13,800 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) announced that on December 9, 2025 its compensation committee granted 13,800 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.

The inducement plan was approved by the board in February 2025 and is being used pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to attract new hires.

Argus Dec 15 session

+1.01% close to close Open Argus

Details

News Market Reaction – FDMT

On Dec 15, the first trading day after this news, FDMT closed 1.01% above the previous close.

Data tracked by StockTitan Argus for the Dec 15 session.

Market Context

This announcement details a modest inducement grant of 13,800 RSUs to three new non-executive employ...

Analysis

This announcement details a modest inducement grant of 13,800 RSUs to three new non-executive employees under the 2025 Employment Inducement Award Plan authorized under Nasdaq Rule 5635(c)(4). It follows a similar RSU grant in November, reflecting ongoing hiring as the company advances late-stage programs. Investors may track cumulative equity awards, recent equity financing activity, and upcoming clinical or partnership milestones when assessing overall dilution and execution risk.

Key Figures

RSUs granted: 13,800 RSUs New employees: 3 employees

RSUs granted

13,800 RSUs

Inducement awards to three new non-executive employees on Dec 9, 2025

New employees

3 employees

Recipients of inducement RSU grants on Dec 9, 2025

Historical Context

5 past events · Latest: Dec 08

5 events

1. Dec 08

   Conference presentation

   24h Move

   +3.5%

   J.P. Morgan Healthcare Conference presentation and webcast availability announcement.

2. Nov 20

   Conference participation

   24h Move

   -4.3%

   Evercore Healthcare Conference fireside chat and investor meetings disclosure.

3. Nov 17

   Executive appointment

   24h Move

   +1.5%

   Appointment of a new CFO to lead finance and strategic initiatives.

4. Nov 14

   Inducement grants

   24h Move

   +1.5%

   RSU awards to new non-executive employees under inducement plan.

5. Nov 10

   Earnings and updates

   24h Move

   -3.1%

   Q3 2025 results with larger loss alongside cash and partnership updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units (RSUs)

1 terms

restricted stock units (RSUs) financial

"granted three new non-executive employees 13,800 Restricted Stock Units (RSUs)."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on December 9, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 13,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did 4D Molecular Therapeutics (FDMT) grant on December 9, 2025?

The company granted 13,800 RSUs to three new non-executive employees.

Under which plan were the FDMT RSUs granted on December 9, 2025?

The RSUs were granted under the company’s 2025 Employment Inducement Award Plan.

When was FDMT’s 2025 Employment Inducement Award Plan approved?

The plan was approved by the board in February 2025.

Why did FDMT use Rule 5635(c)(4) for the December 9, 2025 grants?

Rule 5635(c)(4) permits equity grants to induce new employees to enter employment, which the company used for these RSUs.

How many employees received inducement RSUs from FDMT on December 9, 2025?

Three new non-executive employees received the RSU grants.

Do the December 9, 2025 RSU grants to FDMT employees indicate executive compensation changes?

No; the grants were made to non-executive employees, not to executive officers.